2026-10-28T02:55:32Zhttps://kostu-rdlopen.rawdatalibrary.net/oai/request

oai:kostu-rdlopen.rawdatalibrary.net:kostu/104522026-10-27T23:53:16Zopenairedrivercom_kostu_10000col_kostu_10001com_kostu_10007col_kostu_10059

De novo Drug Design to Suppress Coronavirus RNA-Glycoprotein via PNA-CalcitoninAgar, SoykanAkkurt, BarbarosAlparslan, LeventCoronavirus GlycoproteinCoronavirus RNAHydrogen Contact MappingMolecular DockingMolecular DynamicsSalmon CalcitoninDe novo drug design has been studied utilizing the organic chemical structures of Salmon Calcitonin 9-19 and Peptide Nucleic Acid (PNA) to suppress Coronavirus Ribonucleic Acid (RNA)-Glycoprotein complex. PNA has a polyamide backbone and thymine pendant groups to bind and selectively inhibit adenine domains of the RNA-Glycoprotein complex. While doing so, molecular docking and molecular dynamics studies revealed that there is great inhibition docking energy (-12.1 kcal/mol) with significantly good inhibition constant (124.1 µM) values confirming the efficient nucleotide-specific silencing of Coronavirus RNA-Glycoprotein complex.Turkish Chemical Society2024Articlehttps://rdlopen.rawdatalibrary.net/r/kostu/10452https://doi.org/10.18596/jotcsa.14062902149-0120enJournal of the Turkish Chemical Society, Section A: Chemistryinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://kostu-rdlopen.rawdatalibrary.net/tr/items/kostu/10452